This study is looking at how a special imaging scan, called a PET scan using [18F]F-AraG, can help understand how well immunotherapy (checkpoint inhibitor therapy, or CkIT) is working for people with advanced non-small cell lung cancer (NSCLC). Researchers want to see if changes in the [18F]F-AraG signal on the scan can show how your body is responding to the treatment. You might be able to join if you have advanced NSCLC, are planning to start immunotherapy, and are at least 18 years old. The study aims to see if the scan results match up with how your cancer responds to treatment over one year. The current recruitment status is unclear.

Study design

This is a pilot study involving 20 participants. It is a single-site, open-label, non-randomized, single-arm trial, meaning everyone receives the same intervention and both you and the study team will know what treatment you are getting.

What's involved

You would undergo two PET scans using [18F]F-AraG: one before starting immunotherapy and one while on treatment. You will then be followed for 12 months to check your radiographic and clinical outcomes.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months after treatment to assess radiographic and clinical outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.